The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year. Eli Lilly and Co. said Thursday that it has slated more than $ ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...